Table 2.
Treatment | Percentage of cells with nuclear shape | |||||
---|---|---|---|---|---|---|
Normal appearance | Lobulate | Multinucleate | ||||
Total | Gaps | Total | Gaps | Total | Gaps | |
No drug | 90.8 | 0.3 | 9.2 | 1.3 | 0.0 | |
Taxol 10 nm | ||||||
3 d | 56.4 | 0.2 | 22.2 | 7.7 | 21.4 | 8.4 |
3 d + 3 d | 51 | 0.0 | 26.8 | 1.2 | 22.2 | 2.9 |
3 d + 6 d | 75 | 0.0 | 18.1 | 0.3 | 6.9 | 0.0 |
Taxol 500 nm | ||||||
3 d | 68.7 | 0.0 | 16.6 | 2.1 | 14.7 | 6.9 |
3 d + 3 d | 57.8 | 0.0 | 21.6 | 0.3 | 20.6 | 5.9 |
3 d + 6 d | 75.1 | 0.0 | 13.4 | 0.3 | 11.5 | 3.3 |
Nocodazole | ||||||
3 d | 73.5 | 0.3 | 21.2 | 1.5 | 5.3 | 1.3 |
3 d + 3 d | 81.3 | 0.0 | 18.0 | 0.7 | 0.7 | 0.0 |
3 d + 6 d | 86.0 | 0.0 | 13.2 | 0.3 | 0.8 | 0.3 |
Cells were immunostained for lamin B and nuclear envelope continuity was examined in more than 500 cells using a laser‐scanning confocal microscope. The number of cells with normal‐looking or abnormal‐looking (lobulate and multinucleate) nuclear phenotype (Total) with gaps (Gaps) are expressed as percentage of total interphase cells. Averages of two independent experiments are provided here, totalling at least 1000 cells for each time point.